DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

POLA-R-CHP in the First-line Treatment of Transformed DLBCL

Phase 2

Recruiting

Conditions: Transformed Lymphoma

Interventions: Drug: POLA-R-CHP

First Posted Date: 2024-12-20

Last Posted Date: 2025-02-25

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06743945

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

Phase 2

Not yet recruiting

Conditions: Prostate Cancer Metastatic Disease

Interventions: Drug: HRS-2189
Drug: HRS-5041

First Posted Date: 2024-12-18

Last Posted Date: 2024-12-18

Lead Sponsor: Fudan University

Target Recruit Count: 90

Registration Number: NCT06738745

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2

Not yet recruiting

Conditions: Triple Negative Breast Cancer (TNBC)
Metastatic Breast Cancer

Interventions: Drug: Ivarmacitinib
Drug: Camrelizumab (SHR-1210)
Drug: Eribulin

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT06731153

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Reverse HER2-negative Immune Resistant Breast Cancer

Phase 2

Recruiting

Conditions: HER2 Negative Breast Cancer

Interventions: Drug: Retinoic Acid
Drug: anti-PD-1 antibody and chemotherapy

First Posted Date: 2024-12-12

Last Posted Date: 2025-05-13

Lead Sponsor: Fudan University

Target Recruit Count: 10

Registration Number: NCT06731140

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma

Phase 2

Recruiting

Conditions: Stomach Adenocarcinoma
Gastro-esophageal Junction Cancer

Interventions: Radiation: HFRT targeted to the primary lesion and positive lymph nodes
Radiation: PULSAR targeted to the primary lesion and positive lymph nodes
Drug: Anti-PD-1 monoclonal antibody
Drug: Chemotherapy
Procedure: R0 total/subtotal gastrectomy with D2 lymphadenectomy

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT06728657

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer

Recruiting

Conditions: Breast Cancer
Age

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-20

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT06718010

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

Early Phase 1

Recruiting

Conditions: Advanced Malignant Solid Tumor

Interventions: Biological: IDOV-SAFE

First Posted Date: 2024-12-05

Last Posted Date: 2025-02-06

Lead Sponsor: Fudan University

Target Recruit Count: 38

Registration Number: NCT06718946

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis

Phase 1

Recruiting

Conditions: Breast Cancer Metastatic
Breast Cancer Brain Metastases

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2024-12-05

Last Posted Date: 2025-02-06

Lead Sponsor: Fudan University

Target Recruit Count: 74

Registration Number: NCT06718933

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

Early Phase 1

Not yet recruiting

Conditions: Advanced Malignant Solid Tumor

Interventions: Biological: IDOV-SAFETM

First Posted Date: 2024-12-03

Last Posted Date: 2025-02-06

Lead Sponsor: Fudan University

Target Recruit Count: 42

Registration Number: NCT06713148

Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix.

Phase 2

Not yet recruiting

Conditions: Human Papillomavirus (HPV) Infection
Cervical Cancer

Interventions: Drug: Cnidium Monnieri Detoxification Formula

First Posted Date: 2024-11-26

Last Posted Date: 2024-11-26

Lead Sponsor: Fudan University

Target Recruit Count: 79

Registration Number: NCT06705322

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy